Interferon treatment in children with chronic hepatitis C: Long-lasting remission in responders, and risk for disease progression in non-responders

F. Bortolotti, R. Iorio, G. Nebbia, M. Marcellini, R. Giacchino, L. Zancan, N. Gussetti, C. Barbera, A. Maccabruni, G. Verucchi, F. Balli, A. Vegnente, M. Guido, S. Bartolacci

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background and aim.: Large interferon-based therapeutic trials are still lacking in children with hepatitis C and the long-term safety and efficacy of interferon is unknown. This study describes the outcome of hepatitis C in 43 children enrolled in an open-label interferon trial, and were followed up to 66 months after stopping treatment. Patients and methods.: All patients received interferon alfa2a (5 MU/m2) thrice weekly for 6 months; children with genotype 1b received 3 MU/m2 thrice weekly for 6 additional months. Results.: Nine children discontinued interferon for adverse events and three were not compliant to treatment. Eight (19%, intention to treat analysis), including 2/20 (10%) with genotype 1b and 6/12 (50%) with genotypes 2 or 3, were sustained responders 12 months after stopping therapy. During further follow-up (mean ± S.D.: 44.7 ± 14.6 months), response was maintained; two non-responders cleared viremia, while a young boy progressed to cirrhosis. Conclusions.: Small sample size and therapy withdrawal are the major limitations in the interpretation of our results. Nevertheless, our data, suggesting that response to interferon in children with hepatitis C is genotype-related and stable, agree with the results of large studies in adults. The outcome in non-responders was variable, including persistence of viremia and mild-moderate cytolysis (most cases), progression to cirrhosis, or eventual sustained viremia clearance.

Original languageEnglish
Pages (from-to)336-341
Number of pages6
JournalDigestive and Liver Disease
Volume37
Issue number5
DOIs
Publication statusPublished - May 2005

Fingerprint

Chronic Hepatitis C
Interferons
Disease Progression
Viremia
Hepatitis C
Genotype
Fibrosis
Therapeutics
Intention to Treat Analysis
Sample Size
Outcome Assessment (Health Care)
Safety

Keywords

  • Children
  • Hepatitis C
  • Interferon
  • Therapy of hepatitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Interferon treatment in children with chronic hepatitis C : Long-lasting remission in responders, and risk for disease progression in non-responders. / Bortolotti, F.; Iorio, R.; Nebbia, G.; Marcellini, M.; Giacchino, R.; Zancan, L.; Gussetti, N.; Barbera, C.; Maccabruni, A.; Verucchi, G.; Balli, F.; Vegnente, A.; Guido, M.; Bartolacci, S.

In: Digestive and Liver Disease, Vol. 37, No. 5, 05.2005, p. 336-341.

Research output: Contribution to journalArticle

Bortolotti, F, Iorio, R, Nebbia, G, Marcellini, M, Giacchino, R, Zancan, L, Gussetti, N, Barbera, C, Maccabruni, A, Verucchi, G, Balli, F, Vegnente, A, Guido, M & Bartolacci, S 2005, 'Interferon treatment in children with chronic hepatitis C: Long-lasting remission in responders, and risk for disease progression in non-responders', Digestive and Liver Disease, vol. 37, no. 5, pp. 336-341. https://doi.org/10.1016/j.dld.2004.12.010
Bortolotti, F. ; Iorio, R. ; Nebbia, G. ; Marcellini, M. ; Giacchino, R. ; Zancan, L. ; Gussetti, N. ; Barbera, C. ; Maccabruni, A. ; Verucchi, G. ; Balli, F. ; Vegnente, A. ; Guido, M. ; Bartolacci, S. / Interferon treatment in children with chronic hepatitis C : Long-lasting remission in responders, and risk for disease progression in non-responders. In: Digestive and Liver Disease. 2005 ; Vol. 37, No. 5. pp. 336-341.
@article{9d8ec6f39a704b688f1d7891e73af05c,
title = "Interferon treatment in children with chronic hepatitis C: Long-lasting remission in responders, and risk for disease progression in non-responders",
abstract = "Background and aim.: Large interferon-based therapeutic trials are still lacking in children with hepatitis C and the long-term safety and efficacy of interferon is unknown. This study describes the outcome of hepatitis C in 43 children enrolled in an open-label interferon trial, and were followed up to 66 months after stopping treatment. Patients and methods.: All patients received interferon alfa2a (5 MU/m2) thrice weekly for 6 months; children with genotype 1b received 3 MU/m2 thrice weekly for 6 additional months. Results.: Nine children discontinued interferon for adverse events and three were not compliant to treatment. Eight (19{\%}, intention to treat analysis), including 2/20 (10{\%}) with genotype 1b and 6/12 (50{\%}) with genotypes 2 or 3, were sustained responders 12 months after stopping therapy. During further follow-up (mean ± S.D.: 44.7 ± 14.6 months), response was maintained; two non-responders cleared viremia, while a young boy progressed to cirrhosis. Conclusions.: Small sample size and therapy withdrawal are the major limitations in the interpretation of our results. Nevertheless, our data, suggesting that response to interferon in children with hepatitis C is genotype-related and stable, agree with the results of large studies in adults. The outcome in non-responders was variable, including persistence of viremia and mild-moderate cytolysis (most cases), progression to cirrhosis, or eventual sustained viremia clearance.",
keywords = "Children, Hepatitis C, Interferon, Therapy of hepatitis",
author = "F. Bortolotti and R. Iorio and G. Nebbia and M. Marcellini and R. Giacchino and L. Zancan and N. Gussetti and C. Barbera and A. Maccabruni and G. Verucchi and F. Balli and A. Vegnente and M. Guido and S. Bartolacci",
year = "2005",
month = "5",
doi = "10.1016/j.dld.2004.12.010",
language = "English",
volume = "37",
pages = "336--341",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Interferon treatment in children with chronic hepatitis C

T2 - Long-lasting remission in responders, and risk for disease progression in non-responders

AU - Bortolotti, F.

AU - Iorio, R.

AU - Nebbia, G.

AU - Marcellini, M.

AU - Giacchino, R.

AU - Zancan, L.

AU - Gussetti, N.

AU - Barbera, C.

AU - Maccabruni, A.

AU - Verucchi, G.

AU - Balli, F.

AU - Vegnente, A.

AU - Guido, M.

AU - Bartolacci, S.

PY - 2005/5

Y1 - 2005/5

N2 - Background and aim.: Large interferon-based therapeutic trials are still lacking in children with hepatitis C and the long-term safety and efficacy of interferon is unknown. This study describes the outcome of hepatitis C in 43 children enrolled in an open-label interferon trial, and were followed up to 66 months after stopping treatment. Patients and methods.: All patients received interferon alfa2a (5 MU/m2) thrice weekly for 6 months; children with genotype 1b received 3 MU/m2 thrice weekly for 6 additional months. Results.: Nine children discontinued interferon for adverse events and three were not compliant to treatment. Eight (19%, intention to treat analysis), including 2/20 (10%) with genotype 1b and 6/12 (50%) with genotypes 2 or 3, were sustained responders 12 months after stopping therapy. During further follow-up (mean ± S.D.: 44.7 ± 14.6 months), response was maintained; two non-responders cleared viremia, while a young boy progressed to cirrhosis. Conclusions.: Small sample size and therapy withdrawal are the major limitations in the interpretation of our results. Nevertheless, our data, suggesting that response to interferon in children with hepatitis C is genotype-related and stable, agree with the results of large studies in adults. The outcome in non-responders was variable, including persistence of viremia and mild-moderate cytolysis (most cases), progression to cirrhosis, or eventual sustained viremia clearance.

AB - Background and aim.: Large interferon-based therapeutic trials are still lacking in children with hepatitis C and the long-term safety and efficacy of interferon is unknown. This study describes the outcome of hepatitis C in 43 children enrolled in an open-label interferon trial, and were followed up to 66 months after stopping treatment. Patients and methods.: All patients received interferon alfa2a (5 MU/m2) thrice weekly for 6 months; children with genotype 1b received 3 MU/m2 thrice weekly for 6 additional months. Results.: Nine children discontinued interferon for adverse events and three were not compliant to treatment. Eight (19%, intention to treat analysis), including 2/20 (10%) with genotype 1b and 6/12 (50%) with genotypes 2 or 3, were sustained responders 12 months after stopping therapy. During further follow-up (mean ± S.D.: 44.7 ± 14.6 months), response was maintained; two non-responders cleared viremia, while a young boy progressed to cirrhosis. Conclusions.: Small sample size and therapy withdrawal are the major limitations in the interpretation of our results. Nevertheless, our data, suggesting that response to interferon in children with hepatitis C is genotype-related and stable, agree with the results of large studies in adults. The outcome in non-responders was variable, including persistence of viremia and mild-moderate cytolysis (most cases), progression to cirrhosis, or eventual sustained viremia clearance.

KW - Children

KW - Hepatitis C

KW - Interferon

KW - Therapy of hepatitis

UR - http://www.scopus.com/inward/record.url?scp=24044532949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044532949&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2004.12.010

DO - 10.1016/j.dld.2004.12.010

M3 - Article

C2 - 15843083

AN - SCOPUS:24044532949

VL - 37

SP - 336

EP - 341

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 5

ER -